Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

136 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF; Sirolimus CONVERT Trial Study Group. Schena FP, et al. Among authors: alberu j. Transplantation. 2009 Jan 27;87(2):233-42. doi: 10.1097/TP.0b013e3181927a41. Transplantation. 2009. PMID: 19155978 Clinical Trial.
Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial.
Alberú J, Pascoe MD, Campistol JM, Schena FP, Rial Mdel C, Polinsky M, Neylan JF, Korth-Bradley J, Goldberg-Alberts R, Maller ES; Sirolimus CONVERT Trial Study Group. Alberú J, et al. Transplantation. 2011 Aug 15;92(3):303-10. doi: 10.1097/TP.0b013e3182247ae2. Transplantation. 2011. PMID: 21792049 Clinical Trial.
Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial.
Grinyó JM, Del Carmen Rial M, Alberu J, Steinberg SM, Manfro RC, Nainan G, Vincenti F, Jones-Burton C, Kamar N. Grinyó JM, et al. Among authors: alberu j. Am J Kidney Dis. 2017 May;69(5):587-594. doi: 10.1053/j.ajkd.2016.09.021. Epub 2016 Nov 23. Am J Kidney Dis. 2017. PMID: 27889299 Free article. Clinical Trial.
Individualizing early use of sirolimus in renal transplantation.
Rial Mdel C, Abbud-Filho M, Gonçalves RT, Martinez-Mier G, Montero C, Raffaele P, Toledo Solares M, Alberú J. Rial Mdel C, et al. Among authors: alberu j. Transplant Proc. 2010 Dec;42(10):4518-25. doi: 10.1016/j.transproceed.2010.10.015. Transplant Proc. 2010. PMID: 21168728
Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients.
Vincenti F, Larsen CP, Alberu J, Bresnahan B, Garcia VD, Kothari J, Lang P, Urrea EM, Massari P, Mondragon-Ramirez G, Reyes-Acevedo R, Rice K, Rostaing L, Steinberg S, Xing J, Agarwal M, Harler MB, Charpentier B. Vincenti F, et al. Among authors: alberu j. Am J Transplant. 2012 Jan;12(1):210-7. doi: 10.1111/j.1600-6143.2011.03785.x. Epub 2011 Oct 12. Am J Transplant. 2012. PMID: 21992533 Free article. Clinical Trial.
Markers of inflammation before and after renal transplantation.
Cueto-Manzano AM, Morales-Buenrostro LE, González-Espinoza L, González-Tableros N, Martín-del-Campo F, Correa-Rotter R, Valera I, Alberú J. Cueto-Manzano AM, et al. Among authors: alberu j. Transplantation. 2005 Jul 15;80(1):47-51. doi: 10.1097/01.tp.0000164348.16689.03. Transplantation. 2005. PMID: 16003232
136 results